Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02273765
Other study ID # ANRS 12300 REFLATE TB2
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 11, 2015
Est. completion date November 28, 2018

Study information

Verified date December 2018
Source French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase III trial evaluating raltegravir as an alternative to efavirenz for antiretroviral treatment of HIV-infected patients with tuberculosis.


Description:

Phase III multicenter, international, open-label, randomized trial evaluating non-inferiority of raltegravir at dose of 400mg BID compared to efavirenz 600mg QD, both in association with tenofovir disoproxil fumarate and lamivudine in ART-naïve HIV-1 infected patients with active TB disease receiving a rifampin-based TB treatment initiated <8 weeks before inclusion. Patients will be randomized between 2 arms: the raltegravir (RAL) 400 mg bid arm or the efavirenz (EFV) 600 mg qd arm, each in combination with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) and will be followed for 48 weeks after entry in the trial (ART initiation).


Recruitment information / eligibility

Status Completed
Enrollment 460
Est. completion date November 28, 2018
Est. primary completion date November 28, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Signed informed consent form

- Aged 18 years or more

- Confirmed HIV-1 infection as documented at any time prior to trial entry per national HIV testing procedures

- ART naïve

- For women of childbearing potential i.e. women of childbearing age who are not menopausal, or permanently sterilized (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy) or not refraining from sexual activity: negative urinary test for pregnancy and acceptance to use contraceptive methods

- Confirmed or probable active TB disease of any location, except neurological (meningitis or encephalitis), according to the following criteria based on WHO updated definitions:

- Bacteriologically confirmed pulmonary TB (PTB) or extrapulmonary TB (EPTB), e.g. TB with a biological specimen positive by smear microscopy, culture or nucleic acid amplification test (such as Xpert MTB/RIF).

- Clinically diagnosed PTB or EPTB with typical histological evidence of TB (caseous or granulomatous) on biopsy specimen or positive urinary LAM test OR a significant improvement on TB treatment

- Ongoing standard rifampin-containing TB treatment for =8 weeks at inclusion

- For French patients, affiliation to a Social Security program

Exclusion Criteria:

- HIV-2 co-infection

- Impaired hepatic function (icterus or ALT (SGPT) > 5ULN)

- Hemoglobin < 6.5 g/dl

- Creatinine clearance <60ml/min (assessed by the Cockroft and Gault formula)

- Mycobacterium tuberculosis strain resistant to rifampin (current or past history).

- Neurological TB (meningitis or encephalitis)

- Severe associated diseases requiring specific treatment (including all specific AIDS defining illnesses other than TB, and any severe sepsis)

- Any condition which might, in the investigator's opinion, compromise the safety of treatment and/or patient's adherence to trial procedures including very severe TB-related clinical condition

- Concomitant treatments including phenytoin or phenobarbital (compounds interacting with UGT1A1)

- For HCV co-infected patients, need to start specific treatment for hepatitis during the trial duration

- For women of childbearing potential:

- Pregnancy or breastfeeding

- Refusal to use a contraceptive method

- Any history of ARV intake for prevention of mother to child transmission of HIV (pMTCT)

- Subjects participating in another clinical trial evaluating therapies and including an exclusion period that is still in force during the screening phase

- Person under guardianship, or deprived of freedom by a judicial or administrative decision

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tenofovir + lamivudine + raltegravir
In this arm, patients will receive the following medications : Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd) Raltegravir (RAL) 400 mg (Isentress®): twice daily (1 tablet bid), with food In countries where TDF/3TC FDC is not available, the following separate drugs will be used: Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd) Lamivudine (3TC) : 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd) Raltegravir (RAL) 400 mg (Insentress®): twice daily (1 tablet bid), with food
Tenofovir + lamivudine + efavirenz
In this arm, patients will receive the following medications, in accordance with treatment guidelines in all countries: Tenofovir disoproxil fumarate (TDF) 300 mg / lamivudine (3TC) 300 mg FDC once a day (1 tablet qd) Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd) OR: • Tenofovir disoproxil fumarate (TDF) 245 300 mg / lamivudine (3TC) 300 mg / efavirenz (EFV) 600 mg: once a day (1 tablet qd), at night, if possible without food In countries where TDF/3TC FDC is not available, the following separate drugs will be used: Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd) Lamivudine (3TC): 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd) Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd), if possible without food. The dose will not be adapted to the patient's body weight.

Locations

Country Name City State
Brazil Laboratory of clinical research on STD/AIDS - IPEC/FIOCRUZ Rio de Janeiro
Côte D'Ivoire PACCI / CePReF Centre de Prise en charge de Recherche et de Formation Abidjan
France Hôpital Saint Louis Paris
Mozambique Instituto Nacional de Saude / Hospital Geral de Machava Maputo
Vietnam Pham Ngoc Thach Hospital Ho Chi Minh City

Sponsors (3)

Lead Sponsor Collaborator
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) Merck Sharp & Dohme Corp., Ministry of Health, Brazil

Countries where clinical trial is conducted

Brazil,  Côte D'Ivoire,  France,  Mozambique,  Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients in virologic success Virologic success, defined as plasma HIV-1 RNA <50 copies/mL, at week 48 with a window period of 42 to 54 weeks (snapshot algorithm). Discontinuation of the strategy (ie. permanent discontinuation of EFV, RAL), missing values, loss to follow-up and death will be considered as failure. Week 48
Secondary Time to death Week 48
Secondary Frequency, type and time to new or recurrent AIDS-defining illnesses Week 48
Secondary Frequency, type and time to severe HIV-associated non-AIDS defining illnesses Week 48
Secondary Frequency, type and time to grade 3 or 4 adverse events Week 48
Secondary Frequency, type and time to drug-induced clinical or biological adverse reactions of grade 3 or 4 or leading to treatment interruption Week 48
Secondary Change in plasma HIV-1 RNA from baseline to week 48 Week 48
Secondary Proportion of patients in virologic success at each time point (HIV-1 RNA<50 copies/mL) Week 48
Secondary Time to virologic failure during follow-up Week 48
Secondary Frequency and time to new antiretroviral genotypic resistance in plasma RNA in patients with virologic failure Week 48
Secondary Change in CD4 cell counts from baseline to week 48 Week 48
Secondary Frequency, type and time to Immune Reconstitution Inflammatory Syndrome Week 48
Secondary Frequency of tuberculosis treatment outcomes Week 48
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2